Kornimate/medical-research-clean huggingface dataset:
longitudinal survey analysis in lymphoma survivors

Conditions: Lymphoma; Posttraumatic Stress Disorder; Posttraumatic Growth; Coping; Resilience

Summary: posttraumatic stress disorder (ptsd) is a well-documented phenomenon that occurs in cancer survivors. ptsd is known to cause problems with anxiety, depression, and quality of life. furthermore, there is little treatment available for cancer survivors who suffer from ptsd. posttraumatic growth, however, is a lesser known phenomenon that also occurs in cancer survivors. it is a positive psychological phenomenon that occurs in some people who have suffered a traumatic event--the people who are able to note a "greater appreciation for life", a "stronger relationship with their family/friends," or a "new found level of spirituality" are examples of instances of posttraumatic growth. coping with lymphoma to enhance adjustment and reduce stress in survivors (clear stress) is a study designed to compare the development of ptsd versus the development of posttraumatic growth in lymphoma patients at any stage of the cancer experience, regardless of treatment. the hypothesis is that posttraumatic growth, if it is significant, can reduce the impact of ptsd symptoms in the survivor.


Eligibility criteria:
inclusion criteria: * diagnosis of lymphoma (includes waldenstrom's macroglobulinemia) * can read/write/understand english without a translator exclusion criteria: * currently hospitalized * active psychosis

Keywords: lymphoma survivors posttraumatic growth posttraumatic stress longitudinal
an open-label, rollover study providing continued dosing of gevokizumab in order to assess long-term gevokizumab safety data

Conditions: Uveitis

Summary: the purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.


Eligibility criteria:
inclusion criteria: * completed either the x052130/cl3-78989-005 or the x052131/cl3-78989-006 study's masked d392 or ol-224 completion day visits or had controlled ocular inflammation after having received study drug in part 2 of study x052133 exclusion criteria: * discontinued from the previous study other protocol-defined inclusion/exclusion criteria may apply

Keywords: uveitis non-infectious uveitis intermediate uveitis posterior uveitis panuveitis behçet's disease uveitis
a novel motivational ecological momentary intervention for anorexia nervosa

Conditions: Eating Disorders

Summary: the aim of this study is to pilot an innovative motivational text-message intervention for individuals with anorexia nervosa and subthreshold anorexia nervosa. patients will receive personalized motivational text-messages as an adjunct to cognitive behavioral therapy (cbt). cbt will be provided to patients at no cost for the duration of the study. the investigators hypothesize that the text-messages will help increase motivation to change and kilocalorie intake and decrease eating disordered behavior.


Eligibility criteria:
inclusion criteria: * anorexia nervosa/subthreshold anorexia nervosa (i.e., individuals who exhibit significant dietary restraint) * 18+ years old exclusion criteria: * bmi \< 16.5 * medication instability for 6 weeks * recent/current suicidal risk * comorbid substance abuse or dependence, bipolar disorder, schizophrenia, or mental retardation * inability to provide release of information to a medical provider

Keywords: eating disorders anorexia nervosa treatment technology
ovarian reserve following medical therapy in patients with endometriosis

Conditions: Endometriosis

Summary: this study aims to investigate whether there is an effect on ovarian reserve from medical therapy for endometriosis. although the therapeutic efficacy of medical hormone therapy on ovarian endometriosis has been proven in many scientific studies, none of these has shown an effect on ovarian reserve. the aim of this study is to investigate whether there is a difference in ovarian reserve as measured by biochemical and ultrasound parameters before and after therapy.

endometriosis is a benign, chronic and recurrent condition characterised by the presence of endometrial glands and stroma outside the uterine cavity. endometriosis is most frequently localised to the ovary (17 - 44%) and is found in 5-10% of women of childbearing age. in this group of patients, quantification of the ovarian reserve by means of serological and ultrasound markers, in particular antral follicular count (afc) and blood levels of antimullerian hormone (amh), is essential. recent evidence shows that medical hormone therapy, currently the first choice of treatment, affects ovarian endometriosis in terms of volumetric reduction of endometriomas and reduction of local inflammation, but little is known about its effect on ovarian reserve. our study therefore aims to evaluate ovarian reserve in terms of amh and afc in patients with ovarian endometriosis treated with medical hormone therapy after discontinuation of the latter. in the clinical trial, patients diagnosed with ovarian endometriosis with an indication for medical therapy undergo 3 blood samples for the determination of antimullerian hormone (amh) at the same time as 3 medical examinations as per normal care procedure.

Eligibility criteria:
inclusion criteria: * clinical and ultrasound diagnosis of ovarian endometriosis without indication for surgery * age between 18 and 40 years * patients desiring pregnancy * informed consent obtained exclusion criteria: * endocrinological disorders (including thyroid dysfunction, hyperprolactinaemia and cushing's syndrome) * previous ovarian surgery * suspected cyst malignancy

Keywords: endometriosis medical therapy ovarian reserve
sperm dna fragmentation in recurrent pregnancy loss

Conditions: RECURRENT PREGNANCY LOSS

Summary: in human, 2% of couples experimented recurrent pregnancy loss (rpl). currently, while etiological investigations were performed, 40 to 50 % of rpl were unexplained. in animals' studies, several studies have underlined the importance of sperm quality for a normal embryo development. in human, epidemiological studies have demonstrated that several male risk factors have effects on development (male mediated development toxicology). however, few studies have explored sperm dna fragmentation on embryo development but after in vitro fertilization. in natural pregnancy only rare studies have been performed but with different populations definitions and different methods of sperm exploration. in this context sperm dna fragmentation exploration appears justified. the present study purpose to conduct a case - control study in order to research paternal role in rpl.


Eligibility criteria:
inclusion criteria: * cases: man from couples with rpl (more than 2 miscarriages) rpl classical etiological exploration negative (unexplained rpl) healthy voluntaries * control: man from couples who have a child after a natural pregnancy obtained in the year following child desire. healthy voluntaries exclusion criteria: * cases: etiological exploration of rpl positive man with chromosomal anomaly * cases and controls: ongoing pathology chemotherapy or radiotherapy history hyperthermia (fever) in the last three months pregnancy obtained by assisted reproduction (inseminations, in vitro fertilization) women \> 38 year old
nutritional problems after lung and heart transplantation

Conditions: Bone Density; Overweight

Summary: part 1) bone health after transplantation - possible influence of vitamin k part 2) fat metabolism and endocrine parameters - possible predictors for developement of overweight after transplantation


Eligibility criteria:
inclusion criteria: * accepted for transplantation exclusion criteria: * not accepted for transplantation

Keywords: vitamin k bone mineral density undercarboxylated osteocalcin
hpph photodynamic therapy for patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: phase i study was to investigate the safety and tolerability of the photosensitizer (ps) 2-\[1-hexyloxyethyl\]-2-devinyl pyropheophorbide-a (hpph) for injection in patients with esophageal cancer. it was to characterize the pharmacokinetics of hpph and efficacy of hpph.

the present study is phase i study to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending injection doses of hpph in patients with esophageal cancer. up to 30 patients are planned to be enrolled in 6 cohorts with each cohort consisting of 3-6 patients ( male and/or female patients). in each cohort, patients will receive hpph and lyophilized treatment. the dose escalation in cohorts was from 2.5 to 3, 3.5, 4, 5, and 6mg/m2 of hpph, respectively, administered intravenous drop infusion over 1 hour, once daily, and a fixed light dose of 150 j/cm delivered 48 hours after infusion of hpph.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, male and female subjects with practicing a highly effective form of birth control, and a signed consent; * subjects who was diagnosed as esophageal cancer or carcinoma of gastric cardia by endoscopy and biopsy pathology at t1-t3 stage. * subjects who could not be taken surgery or chemotherapy; with unsucessful surgery or failed chemotherapy; who had refused surgery and chemotherapy * ecog 0-2, life expectancy would be more than 3-month exclusion criteria: * subjects were diagnosed as tracheoesophageal fistula or esophageal mediatinal fistula, or more than 60 years old with having three kinds of heart, lung, liver and kidney commorbities; * hematopoietic wbc \< 3×109/l; hgb \<80g/l; plt \<80×109/l; plt \<1.5 times upper limit of normal (uln) * hepatic tbil\>1.5uln, alt or ast \>2.5 uln * alkaline phosphatase \> 3 times uln * uncontrol hypertension: bp\>160/100mmhg * uncomtrol diabetes

Keywords: phhp esophageal cancer phase i study
manual therapy and rehabilitation on pain and physical functioning for chronic knee pain

Conditions: Non-Specific Chronic Knee Pain

Summary: this is a research study examining if hands-on therapy and prescribed exercise is an effective way to manage and reduce knee pain. it will also look at physical benefits of this treatment including balance, strength, and flexibility. participation will include 2 assessment days and a 12-week treatment cycle. assessments will be conducted during week 1 and after treatment. the treatment will vary based on the assigned group. this may include 12 in-person manual therapy sessions occurring once per week and or 12-weeks of at-home therapy occurring 5 times per week. the greatest risk of participation includes possible muscle/joint soreness, injury during at-home exercises, and loss of confidentiality.


Eligibility criteria:
inclusion criteria: * adults experiencing non-specific knee pain for 3 or more months. pain must be 3/10 (vas) or higher. exclusion criteria: * pain due to knee surgery, fracture, tumor, trauma, or those on medication for mood disorder (assessed on case by case basis).
study to evaluate the efficacy and safety of pf-07055480 / giroctocogene fitelparvovec gene therapy in moderately severe to severe hemophilia a adults

Conditions: Hemophilia A

Summary: c3731003 is a pivotal phase 3 study to evaluate the clinical efficacy and safety of a single iv infusion of pf-07055480 / giroctocogene fitelparvovec (recombinant aav2/6 human factor viii gene therapy) in adult male participants with moderately severe or severe hemophilia a (fviii:c≤1%) for the study duration of 5 years. the study will enroll eligible participants who have been followed on routine prophylaxis with fviii products in the lead-in study c0371004.


Eligibility criteria:
main inclusion criteria * males who have been followed on routine factor viii prophylaxis therapy during the lead-in study (c0371004) and have \> = 150 documented exposure days to a factor viii protein product * moderately severe to severe hemophilia a (factor viii activity \< =1%) * suspension of fviii prophylaxis therapy post study drug infusion main exclusion criteria * anti-aav6 neutralizing antibodies * history of inhibitor to factor viii * laboratory values at screening visit that are abnormal or outside acceptable study limits * significant and/or unstable liver disease, biliary disease, significant liver fibrosis * conditions associated with increased thromboembolic risk such as inherited or acquired thrombophilia, or a history of thrombotic events * planned surgical procedure requiring factor viii surgical prophylactic factor treatment 12 months from screening visit * active hepatitis b or c * serological evidence of human immunodeficiency virus hiv-1 or hiv-2 with cluster of differentiation 4 positive (cd4+) cell count ≤200 mm3 and/or viral load \>20 copies/ml

Keywords: pf-07055480 sb-525 hemophilia factor viii fviii gene therapy aav aav6 annualized bleeding rate abr giroctocogene fitelparvovec affine
triple therapy prevention of recurrent intracerebral disease events trial magnetic resonance imaging sub-study

Conditions: Stroke; Cerebral Small Vessel Diseases; Intracerebral Hemorrhage; Vascular Dementia; Hypertension

Summary: trident main study: trident is a multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial of a fixed low-dose combination bp-lowering pill ("triple pill") strategy on top of standard of care, in patients with a history of acute intracerebral haemorrhage (ich) and systolic blood pressure (sbp) levels defined as 'high normal to borderline high', and on either minimal or no bp-lowering treatment according to current guidelines. mri sub-study centres capable of specific mri of the brain sequences will be identified. the patients in the trident main study who are identified to be eligible for the mri sub-study will undergo mri scans at baseline (6 weeks to 6 months post-randomisation) and at 36-month follow-up time points. all data collected will be analysed centrally at the brain and mind centre (bmc) in sydney, australia.

intracerebral haemorrhage (ich) is the most serious type of stroke, accounting for 10% of stroke in high-income countries and up to 50% in low-to-middle income countries, especially in asia where hypertension is common. ich in the context of hypertension is often a manifestation of underlying cerebral small vessel disease (csvd). in summary, there is a considerable body of evidence supporting and association of csvd with hypertension and poor outcomes, but limited evidence as to whether good bp control can modify the natural history of this condition.

Eligibility criteria:
inclusion criteria: 1. eligible for, randomised and continuing in trident main study 2. no contraindications to mri scan of the brain 3. provide informed consent for the mri sub-study exclusion criteria: 1. any mri contraindications (e.g. metallic implants, claustrophobia, etc.) 2. less than 6 weeks or greater than 6 months post-randomisation (however, where possible the baseline mri sub-study scan should be conducted as soon as possible after the qualifying ich. e.g. if the qualifying ich was 4 months prior to randomisation, the baseline scan should be done as close to 6 weeks post-randomisation as possible)
detect-rpc universal em screening

Conditions: Elder Abuse; Elder Mistreatment

Summary: the purpose of this study is to evaluate whether the use of the detection of elder mistreatment through emergency care technicians-revised for primary care (detect-rpc) screening tool increases the average reporting of elder mistreatment (em) by homebased primary care (hbpc) clinicians.


Eligibility criteria:
inclusion criteria (clinicians): * clinician who actively provides home-based primary care (hbpc) to patients enrolled in one of our partner home-based primary care programs at least part time. exclusion criteria (clinicians): * hbpc clinicians must be a physician, nurse practitioner, or physician assistant who actively provides home-based primary care to patients enrolled at a partner site hbpc at least part time inclusion criteria (patients): * in home-based primary care * 60 years or older * seen by a clinician participating in the study exclusion criteria (patients) * must be aged 60 and older, enrolled in a site-specific partner hbpc and treated in their primary residence

Keywords: elder mistreatment
the feasibility and safety of avoiding chest tube placement after video-assisted thoracoscopic surgery (vats）of the lung

Conditions: Lung Diseases

Summary: this is a prospective randomized controlled trial.the main study content is the feasibility and safety of avoiding chest tube placement after video-assisted thoracoscopic surgery lung disease,participants were randomly divided into experimental group and control group.avoiding chest tube placement after vats of the lung in the experimental group.indwelling thoracic drainage tube after vats of the lung in the control group.

this is a prospective randomized controlled trial.the main study content is the feasibility and safety of avoiding chest tube placement after vats of the lung,divided into experiment group and control group.communicating with surgeon and patients who met the inclusion criteria,decided whether to enter the experimental group or control group. experimental group avoid chest tube placement after vats of the lung and control group indwell thoracic drainage tube after vats of the lung.by collecting personal information of two groups of patients and the corresponding observation indicators to analyze whether the treatment of avoiding chest tube placement after vats of the lung is more beneficial than the conventional indwell thoracic drainage tube after vats of the lung,and it's safe and feasible.

Eligibility criteria:
inclusion criteria: - 1.age ranges from 18 to 75 years old,do the examination of chest ct showed pulmonary disease,no invasion of peripheral blood vessels and viscera,no pleural effusion and pericardial effusion. 2.electrocardiogram, pulmonary function,color doppler ultrasound of the heart,arteries and veins of both lower limbs are normal,no potential infection was confirmed before surgery, no serious organic disease of the heart and lung,and no obvious operation contrain. exclusion criteria: * 1.the lungs continue to leak air preoperation more than six days. 2.the appearment of the hemothorax,empyema and chylothorax preoperative. 3.the appearment of the preoperative chest x-ray pulmonary atelectasis and pulmonary infection. 4.the lungs leak air appears in the surgery. 5.patients with severe cardiovascular and cerebrovascular accident after operation were terminated. 6.impaired lung function (forced expiratory volume in 1 second \[fev1\]\<60% predicted).

Keywords: postoperative pain avoiding chest drainage placement hospital cost
colorectal cancer dataset in xijing hospital from 2011

Conditions: Prognostic Cancer Model; Chemotherapy; Nutrition Related Cancer

Summary: to compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the xijing hospital.


Eligibility criteria:
inclusion criteria: * 1. pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as lynch syndrome and familial adenocarcinoma tumor polyposis, peutz jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome; * 2. visit our center with complete medical records and pathological information; * 3. colorectal cancer patients diagnosed between 2013 and 2023. exclusion criteria: * 1. the patient has other colorectal malignancies other than adenocarcinoma; * 2. malignant tumors adjacent to organs invading the colon and rectum; * 3. malignant tumors from distant organs metastasize to the colon and rectum; * 4. benign colorectal lesions; 5. patients with recurrent colorectal cancer.
stage i/ii nsclc perioperative chemotherapy

Conditions: Non-small Cell Lung Cancer Stage I and II; Peri-operative Chemotherapy

Summary: the addition of chemotherapy to lung cancer surgery is now considered as the standard of care. solid data support postoperative chemotherapy but only few results are available in the preoperative setting. to define which timing of perioperative chemotherapy offers the best survival improvement, the ifct 0002 study is conducted in france.

in this multicenter study, patients are randomized to receive either two preoperative chemotherapy cycles plus two additional preoperative cycles if they respond to chemotherapy, or two preoperative plus two postoperative cycles in case of response.

Eligibility criteria:
inclusion criteria: histologically or cytologically nsclc stade i or ii resectable disease who performance status of 2 or less exclusion criteria: nsclc stage iii or iv
the effect of allergen immunotherapy on exhaled nitric oxide in adult patients with asthma and allergic rhinitis

Conditions: Allergic Asthma; Allergic Rhinitis

Summary: this study will evaluate whether exhaled nitric oxide levels are affected by allergen immunotherapy ("allergy shots"). the investigators' hypothesis is that successful allergen immunotherapy may be accompanied by decreased exhaled nitric oxide levels.


Eligibility criteria:
inclusion criteria: * subjects over 18 years old with allergic asthma and/or allergic rhinitis who are beginning allergen desensitization exclusion criteria: * smokers * subjects of dimished capacity
sdoct-gmpe software

Conditions: Glaucoma

Summary: the investigators prospectively evaluate the new glaucoma premium edition (gmpe) software for spectral domain optical coherence tomography (sdoct) and if this software is superior to the conventional one that is currently used for sdoct.

the new gmpe software can now identify the ocular structures without input from the operator thus reducing operator induced errors. it also measures the thickness of the entire optic nerve head so as to allow for another anatomic area of the eye to be measured for assessment of glaucoma. in addition, it permits collection of retinal nerve fiber layer thickness data in three concentric circles instead of just one in order to account for different sizes of optic nerves. subjects who are receiving routine sdoct (cpt 92133) will be recruited from the duke eye center and its associated satellite clinics. following informed consent, subjects undergo additional imaging using the sdoct-gmpe software at the duke eye center and its associated satellite clinics. the imaging results may be used in clinical care for the subjects.

Eligibility criteria:
inclusion criteria: * capable and willing to provide consent * history of clinically-diagnosed glaucoma * at least 18 years of age exclusion criteria: * unable or unwilling to give consent * under 18 years of age

Keywords: glaucoma oct spectral domain optical coherence tomography